# A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol

> **NCT00645151** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 512 (actual)

## Conditions studied

- Dyslipidemias

## Interventions

- **DRUG:** Atorvastatin
- **DRUG:** Atorvastatin
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT00645151
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** 2005-02
- **Target enrollment:** 512 (ACTUAL)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00645151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00645151, "A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00645151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*